Invivyd (IVVD) News Today $0.90 +0.15 (+20.15%) Closing price 04:00 PM EasternExtended Trading$0.88 -0.02 (-2.03%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVVD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 VirusMay 27 at 7:01 AM | globenewswire.comInvivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell LymphomasMay 23, 2025 | globenewswire.comInvivyd Commends FDA on New Framework for COVID-19 Vaccines Amidst Uncertainty Regarding Booster EfficacyMay 23, 2025 | nasdaq.comInvivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19May 21, 2025 | globenewswire.comInvivyd's (IVVD) Buy Rating Reiterated at D. Boral CapitalMay 19, 2025 | americanbankingnews.comEarnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings missMay 16, 2025 | investing.comInvivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ...May 16, 2025 | finance.yahoo.comInvivyd Reports Q1 2025 Financial Results and OutlookMay 16, 2025 | tipranks.comINVIVYD Earnings Preview: Recent $IVVD Insider Trading, Hedge Fund Activity, and MoreMay 15, 2025 | nasdaq.comInvivyd, Inc. (IVVD) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comOrbimed Advisors LLC Decreases Stock Position in Invivyd, Inc. (NASDAQ:IVVD)Orbimed Advisors LLC lessened its stake in Invivyd, Inc. (NASDAQ:IVVD - Free Report) by 33.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,149,300 shares of the company's stock after selling 579,000 shareMay 15, 2025 | marketbeat.comInvivyd Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 15, 2025 | globenewswire.comMithril II GP LP Buys New Shares in Invivyd, Inc. (NASDAQ:IVVD)Mithril II GP LP bought a new stake in shares of Invivyd, Inc. (NASDAQ:IVVD - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 11,241,580 shares of the company's stock, valued at approximately $4May 15, 2025 | marketbeat.comInvivyd, Inc. Submits Citizen Petition to FDA Advocating for Updated COVID-19 Vaccine Development StrategiesMay 14, 2025 | quiverquant.comInvivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine EfficacyMay 14, 2025 | globenewswire.comInvivyd Initiates Discovery Program for Monoclonal Antibody Targeting Measles Infection and ProphylaxisMay 13, 2025 | nasdaq.comInvivyd begins discovery of measles monoclonal antibodyMay 13, 2025 | investing.comInvivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor ConferenceMay 13, 2025 | globenewswire.comInvivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for MeaslesMay 12, 2025 | globenewswire.comInvivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025May 8, 2025 | globenewswire.comShort Interest in Invivyd, Inc. (NASDAQ:IVVD) Drops By 15.1%Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) saw a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 7,010,000 shares, a decline of 15.1% from the March 31st total of 8,260,000 shares. Currently, 9.2% of the company's shares are sold short. Based on an average daily volume of 14,470,000 shares, the short-interest ratio is presently 0.5 days.May 5, 2025 | marketbeat.comInvivyd (IVVD) to Release Earnings on ThursdayInvivyd (NASDAQ:IVVD) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-invivyd-inc-stock/)May 3, 2025 | marketbeat.comInvivyd, Inc. (NASDAQ:IVVD) Short Interest Up 24.0% in MarchInvivyd, Inc. (NASDAQ:IVVD - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 8,260,000 shares, an increase of 24.0% from the March 15th total of 6,660,000 shares. Currently, 10.9% of the company's stock are short sold. Based on an average daily volume of 14,600,000 shares, the days-to-cover ratio is presently 0.6 days.April 22, 2025 | marketbeat.comInvivyd announces $30M non-dilutive loan facilityApril 21, 2025 | markets.businessinsider.comWhat's Going On With Invivyd Stock On Monday?April 21, 2025 | benzinga.comInvivyd Secures $30 Million Loan from SVBApril 21, 2025 | tipranks.comInvivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley BankApril 21, 2025 | globenewswire.comInvivyd, Inc. (NASDAQ:IVVD) Sees Large Decline in Short InterestInvivyd, Inc. (NASDAQ:IVVD - Get Free Report) was the recipient of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 6,660,000 shares, a decrease of 28.8% from the February 28th total of 9,360,000 shares. Approximately 8.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 14,530,000 shares, the short-interest ratio is currently 0.5 days.March 31, 2025 | marketbeat.comInvivyd adds venture capitalist Ajay Royan to boardMarch 29, 2025 | uk.investing.comHC Wainwright Reaffirms Buy Rating for Invivyd (NASDAQ:IVVD)HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Invivyd in a report on Wednesday.March 27, 2025 | marketbeat.comInvivyd Appoints Ajay Royan to Board of DirectorsMarch 26, 2025 | tipranks.comInvivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of DirectorsMarch 26, 2025 | globenewswire.comInvivyd's (IVVD) "Buy" Rating Reiterated at D. Boral CapitalD. Boral Capital reissued a "buy" rating and set a $9.00 target price on shares of Invivyd in a report on Thursday.March 21, 2025 | marketbeat.comInvivyd reports FY24 EPS ($1.43) vs. ($1.81) last yearMarch 21, 2025 | markets.businessinsider.comInvivyd (NASDAQ:IVVD) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPSInvivyd (NASDAQ:IVVD - Get Free Report) released its earnings results on Thursday. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.10.March 21, 2025 | marketbeat.comInvivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business HighlightsMarch 20, 2025 | globenewswire.comInvivyd (IVVD) Projected to Post Earnings on ThursdayInvivyd (NASDAQ:IVVD) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comAre Investors Undervaluing Invivyd, Inc. (IVVD) Right Now?March 12, 2025 | msn.comInvivyd (NASDAQ:IVVD) Receives Buy Rating from D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Invivyd in a report on Wednesday.March 6, 2025 | marketbeat.comInvivyd, Inc. (NASDAQ:IVVD) Short Interest UpdateInvivyd, Inc. (NASDAQ:IVVD - Get Free Report) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 8,510,000 shares, a growth of 28.5% from the January 31st total of 6,620,000 shares. Currently, 11.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 13,950,000 shares, the days-to-cover ratio is presently 0.6 days.March 6, 2025 | marketbeat.comInvivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1March 5, 2025 | finanznachrichten.deInvivyd announces in vitro neutralization data for PEMGARDAMarch 5, 2025 | markets.businessinsider.comInvivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1March 5, 2025 | globenewswire.comInvivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 AntibodyMarch 4, 2025 | finance.yahoo.comWhy Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025March 2, 2025 | msn.comH.C. Wainwright Reaffirms Their Buy Rating on Invivyd (IVVD)February 25, 2025 | markets.businessinsider.comInvivyd, Inc.: FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA (pemivibart)February 25, 2025 | finanznachrichten.deInvivyd Shares Down as Regulators Decline Expanded Use for Covid-19 TreatmentFebruary 25, 2025 | marketwatch.comInvivyd says FDA declines request to expand existing EUA of PEMGARDAFebruary 25, 2025 | markets.businessinsider.comInvivyd shares drop as FDA declines company's COVID-19 treatment EUA expansionFebruary 25, 2025 | msn.com Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address IVVD Media Mentions By Week IVVD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVVD News Sentiment▼0.311.02▲Average Medical News Sentiment IVVD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVVD Articles This Week▼52▲IVVD Articles Average Week Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RAPP News Today ATAI News Today URGN News Today ORIC News Today MREO News Today BNTC News Today SNDL News Today TKNO News Today CKPT News Today ERAS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IVVD) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IVVD Stock Free IVVD Stock Alerts